RENOVA iStim™

Neuromodulation is a long standing therapy with years of accumulated experience and demonstrated effectiveness. Now, physicians and patients are ready for a new product in a form factor that will unlock the enormous potential of the therapy.

Renova - for the treatment of patients with Overactive Bladder

RENOVA iStim™ – for the treatment of patients with Overactive Bladder and associated symptoms of urinary urgency and frequency, with or without urge incontinence.

 

RENOVA iStim™ – for the treatment of patients with Overactive Bladder and associated symptoms of urinary urgency and frequency, with or without urge incontinence.

Learn More

 

 

RENOVA iStim™ Stimulator

A miniature implant which is battery-less and wirelessly powered and which delivers targeted electric stimulation to the posterior tibial nerve

The Stimulator
Patient Wearable

Patient Wearable

Wirelessly powering the Stimulator

Clinician Programmer

Clinician Programmer

Enabling the clinician full control of stimulation parameters to optimize the therapy for the patient

BlueWind Medical’s Competitive Advantages

Miniature

Miniature

Miniature

The Bluewind Medical neurostimulator is significantly smaller than conventional devices. Advanced technologies allow the transformation to a minimally invasive procedure.

Leadless

Leadless

Leadless

No wires tunneled under the skin thus avoiding lead migration or fracture.

Battery-less

Battery-less

Battery-less

Patient wearable provides wireless power without the need for repeated surgeries to replace a depleted battery.

Fully featured

Fully featured

Fully featured

The BlueWind Medical device incorporates the latest technological advancements in neuromodulation.

Expanding access

Expanding access

Expanding access

The easier procedure and smaller implant support a growing number of indications and  increased access to therapy.

MR safe

MR safe

MR safe

MR conditional for static magnetic field of 1.5 and 3 Tesla.

Market for Overactive Bladder therapy

The opportunity for growth in the $700 Million Overactive Bladder (OAB) Neuromodulation market is vast.
14.3 Million patients in the US suffer from OAB and are refractory to medication, of which only 150,000 patients are treated with neuromodulation. This is primarily due to the complexity, invasiveness, complications and cost of existing solutions. BlueWind Medical is poised to capitalize on this market need, leveraging its technological advantages and unique design to treat many more patients.

Market for Overactive Bladder therapy